Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19148315 | 0.98 | HSD17B10 (0.48) | HSD17B10RAB9AKMT2AMEN1KDM4E | |
| Trifluoroacetic Acid SCHEMBL19711908 | 0.88 | HSD17B10 (0.41) | HSD17B10RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL29606285 | 0.83 | KMT2A (0.38) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL4138150 | 0.81 | HSD17B10 (0.50) | HSD17B10KDM4ESLC6A9CYP1A2ALDH1A1 | |
| SCHEMBL6320482 | 0.79 | KDM4E (0.54) | RAB9AKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL16118877 | 0.79 | KMT2A (0.36) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL7345543 | 0.79 | KMT2A (0.36) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL12226477 | 0.79 | KMT2A (0.40) | RAB9AKMT2AMEN1KDM4ECYP1A2 | |
| Tetraxetan SCHEMBL18018 | 0.79 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9CYP1A2ALDH1A1 | |
| SCHEMBL173508 | 0.79 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630406-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024121046-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| CN-114583263-B | Electrolyte, positive electrode, lithium ion battery and vehicle | 比亚迪股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230139056-A1 | METHODS, COMPOSITIONS AND REAGENTS FOR PREPARING COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4011880-A1 | JAK KINASE INHIBITOR AND USE THEREOF | Jiangsu Carephar Pharmaceutical Co., Ltd (CN) | 2022-06-15 | — | — | EP | disclosed |
| CN-114583263-A | Electrolyte, positive electrode, lithium ion battery and vehicle | 比亚迪股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-20110129777-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| US-20080200460-A1 | Chemical Compounds | BROWN DEARG | 2008-08-21 | — | — | US | disclosed |
| WO-2008065068-A2 | SUBSTITUTED DIHYDROIMIDAZOLES AND THEIR USE IN THE TREATMENT OF TUMORS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |
| US-6265575-B1 | THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6251921-B1 | ADMINISTERING THROMBIN INHIBITING DIAMINE COMPOUND TO MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6025382-A | Antithrombotic diamines | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | TP53, KRAS, NRAS | HSD17B10 3626/4885RAB9A 267/4885KMT2A 4335/4885 |
| US-20080200460-A1 | Chemical Compounds | CCR5, CXCR4, CXCR5 | HSD17B10 2020/4885RAB9A 3476/4885KMT2A 3591/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | HSD17B10 1951/4885RAB9A 3073/4885KMT2A 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.